CHAD LANDMON is a Partner at Axinn, Veltrop & Harkrider LLP, where he chairs the FDA and IP Practice Groups.  Mr. Landmon has extensive experience in food and drug law and patent litigation and counseling.  His patent litigation practice is national in scope and concentrates on the life sciences industry.  Mr. Landmon maintains a particular focus on Paragraph IV litigation.  Mr. Landmon provides counseling and litigation services relating to patent, FDA and antitrust issues involving the development and marketing of new and generic drug products.  He has litigated a wide variety of Paragraph IV cases in numerous jurisdictions, including cases involving blockbuster drugs.  His FDA matters involve petitioning FDA and litigating issues relating to the Hatch-Waxman Act, including marketing exclusivities, patent listing, certification and notification requirements, bioequivalence, labeling and other issues relevant to the FDA drug approval process.  Mr. Landmon’s practice also includes matters involving the intersection of the antitrust and patent laws, such as issues arising from the settlement of patent and Hatch-Waxman exclusivity disputes.  Mr. Landmon frequently speaks and writes about issues relating to the Hatch-Waxman Act and pharmaceutical patent litigation.